SecBot SecBot
8-K ·Filed Jun 15, 2026

GIPL

Global Innovative Platforms Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001376474-26-000442
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for FINRA 15c2-11 approval, which could improve OTC liquidity, and for study results expected by year-end 2026. The going concern qualification in the prior 10-Q remains a risk; watch for any capital raise announcements.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
GIPL ▲ 0.00% at T+60d
NEUTRAL call 0.00% · α vs SPY -1.26% · entry $0.5000 → $0.5000
Entry = T+0 close
Jun 15, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.60%
$0.5000
settled 4mo ago
T+5d
-0.02%
call -0.02% · α +2.60%
$0.4999
settled 4mo ago
T+20d
-0.02%
call -0.02% · α +0.12%
$0.4999
settled 4mo ago
T+60d
0.00%
call 0.00% · α -1.26%
$0.5000
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Global Innovative Platforms issued a shareholder update via 8-K Item 7.01, detailing progress on its VetBreath Analytics diagnostic platform. Key developments include a FINRA 15c2-11 application submitted June 12, 2026, a new collaboration with Big Dog Ranch Rescue, and seating of the board of directors. The company reported $136,500 in revenue for the six months ended March 31, 2026, and stated it has sufficient capital through end of 2026, though the prior 10-Q includes a going concern qualification. No material financial guidance or hard catalysts were provided.

Key Facts

  • Revenue for six months ended March 31, 2026 totaled $136,500
  • Revenue-producing collaboration extended through July 2026 at ~$15,000–$18,000 per month
  • FINRA 15c2-11 application submitted by Glendale Securities on June 12, 2026
  • Board of Directors formally seated effective April 1, 2026
  • Selected for Plug and Play incubator program; won pitch competition in late May 2026
  • Big Dog Ranch Rescue joined as sample collection partner on June 3, 2026
  • Company has sufficient capital to sustain operations through end of 2026
  • Prior Form 10-Q includes a going concern qualification

Financial Impact

Minimal; revenue run-rate ~$180,000–$216,000 annually from existing collaboration, no new financial guidance provided

revenue

Risk Factors

  • Going concern qualification in prior 10-Q filing
  • No assurance FINRA 15c2-11 application will be approved
  • Studies may not be completed on expected timeline or yield successful results
  • Minimal revenue and pre-commercialization stage

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001376474-26-000442
Document: gipl-20260615_8k.htm0001376474-26-000442
Document: 0001376474-26-000442-index-headers.html0001376474-26-000442
Document: 0001376474-26-000442-index.html0001376474-26-000442
Document: 0001376474-26-000442.txt0001376474-26-000442
3 reports for GIPL
Performance horizon
Filters
Rows
Reports for GIPL — sortable, filterable
TypeNow
Oct 6, 2026
21d ago
8-K
NEUTRAL ★ 2/10
$0.5000awaiting T+20—$0.5000 (0.00%)
Jun 15, 2026
19w ago
8-K
NEUTRAL ★ 3/10
$0.5000 $0.4999▼ −0.02%▲ +0.12%$0.5000 (0.00%)
May 20, 2026
22w ago
8-K
NEUTRAL ★ 2/10
$0.5000 $0.5000· 0.00%▼ −0.33%$0.5000 (0.00%)
Showing 3 of 3

US Market Status

Market Closed — Opens Thu (11h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026